JPWO2019045897A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019045897A5 JPWO2019045897A5 JP2020512589A JP2020512589A JPWO2019045897A5 JP WO2019045897 A5 JPWO2019045897 A5 JP WO2019045897A5 JP 2020512589 A JP2020512589 A JP 2020512589A JP 2020512589 A JP2020512589 A JP 2020512589A JP WO2019045897 A5 JPWO2019045897 A5 JP WO2019045897A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- lipid
- cationic lipid
- molar ratio
- helper
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 99
- 150000002632 lipids Chemical class 0.000 claims description 61
- -1 cationic lipid Chemical class 0.000 claims description 55
- 210000004027 cell Anatomy 0.000 claims description 39
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 28
- 239000012867 bioactive agent Substances 0.000 claims description 17
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 235000012000 cholesterol Nutrition 0.000 claims description 14
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 4
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 3
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 150000008105 phosphatidylcholines Chemical class 0.000 claims description 2
- 229940067605 phosphatidylethanolamines Drugs 0.000 claims description 2
- 239000003623 enhancer Substances 0.000 claims 20
- 108010081734 Ribonucleoproteins Proteins 0.000 claims 18
- 102000004389 Ribonucleoproteins Human genes 0.000 claims 18
- 108020004707 nucleic acids Proteins 0.000 claims 17
- 102000039446 nucleic acids Human genes 0.000 claims 17
- 150000007523 nucleic acids Chemical class 0.000 claims 17
- 239000002202 Polyethylene glycol Substances 0.000 claims 16
- 229920001223 polyethylene glycol Polymers 0.000 claims 16
- CTSWAPPGGOUWHA-UHFFFAOYSA-N N-(3-aminopropyl)-N'-[3-(dihydroxyamino)propyl]-N,N'-di(tetradecyl)butane-1,4-diamine Chemical compound ON(CCCN(CCCCN(CCCN)CCCCCCCCCCCCCC)CCCCCCCCCCCCCC)O CTSWAPPGGOUWHA-UHFFFAOYSA-N 0.000 claims 12
- VHKGFFKMYUUZGS-UHFFFAOYSA-N 4-(3-aminopropylamino)-1-[di(tetradecyl)amino]butan-1-ol Chemical compound OC(N(CCCCCCCCCCCCCC)CCCCCCCCCCCCCC)CCCNCCCN VHKGFFKMYUUZGS-UHFFFAOYSA-N 0.000 claims 11
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 210000004072 lung Anatomy 0.000 claims 7
- 230000000975 bioactive effect Effects 0.000 claims 6
- 108091033409 CRISPR Proteins 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 210000002889 endothelial cell Anatomy 0.000 claims 4
- 210000002919 epithelial cell Anatomy 0.000 claims 4
- 125000004404 heteroalkyl group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 108020004999 messenger RNA Proteins 0.000 claims 4
- 108020005004 Guide RNA Proteins 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 241000288906 Primates Species 0.000 claims 2
- 241000283984 Rodentia Species 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 150000001450 anions Chemical class 0.000 claims 2
- 239000000032 diagnostic agent Substances 0.000 claims 2
- 229940039227 diagnostic agent Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 108091070501 miRNA Proteins 0.000 claims 2
- 239000002679 microRNA Substances 0.000 claims 2
- 150000003904 phospholipids Chemical class 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 claims 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims 1
- 239000004721 Polyphenylene oxide Substances 0.000 claims 1
- 229940106189 ceramide Drugs 0.000 claims 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims 1
- 229930183167 cerebroside Natural products 0.000 claims 1
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 claims 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 claims 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920000570 polyether Polymers 0.000 claims 1
- 210000004879 pulmonary tissue Anatomy 0.000 claims 1
- 229940063673 spermidine Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 2
- DSNRWDQKZIEDDB-GCMPNPAFSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-GCMPNPAFSA-N 0.000 description 2
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 description 1
- WTBFLCSPLLEDEM-JIDRGYQWSA-N 1,2-dioleoyl-sn-glycero-3-phospho-L-serine Chemical group CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC WTBFLCSPLLEDEM-JIDRGYQWSA-N 0.000 description 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 1
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 description 1
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- KLFKZIQAIPDJCW-HTIIIDOHSA-N Dipalmitoylphosphatidylserine Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCC KLFKZIQAIPDJCW-HTIIIDOHSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- FVJZSBGHRPJMMA-IOLBBIBUSA-N PG(18:0/18:0) Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-IOLBBIBUSA-N 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 description 1
- FRKBLBQTSTUKOV-UHFFFAOYSA-N diphosphatidyl glycerol Natural products OP(O)(=O)OCC(OP(O)(O)=O)COP(O)(O)=O FRKBLBQTSTUKOV-UHFFFAOYSA-N 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 150000008106 phosphatidylserines Chemical class 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
Images
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023115742A JP2023138526A (ja) | 2017-08-31 | 2023-07-14 | 組織特異的送達用のカチオン性脂質組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762552783P | 2017-08-31 | 2017-08-31 | |
| US62/552,783 | 2017-08-31 | ||
| PCT/US2018/042555 WO2019045897A1 (en) | 2017-08-31 | 2018-07-17 | CATIONIC LIPIDIC COMPOSITIONS FOR TISSUE-SPECIFIC ADMINISTRATION |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023115742A Division JP2023138526A (ja) | 2017-08-31 | 2023-07-14 | 組織特異的送達用のカチオン性脂質組成物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2020532546A JP2020532546A (ja) | 2020-11-12 |
| JP2020532546A5 JP2020532546A5 (https=) | 2022-12-09 |
| JPWO2019045897A5 true JPWO2019045897A5 (https=) | 2022-12-09 |
| JP7379325B2 JP7379325B2 (ja) | 2023-11-14 |
Family
ID=63104088
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020512589A Active JP7379325B2 (ja) | 2017-08-31 | 2018-07-17 | 組織特異的送達用のカチオン性脂質組成物 |
| JP2023115742A Pending JP2023138526A (ja) | 2017-08-31 | 2023-07-14 | 組織特異的送達用のカチオン性脂質組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023115742A Pending JP2023138526A (ja) | 2017-08-31 | 2023-07-14 | 組織特異的送達用のカチオン性脂質組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20190060482A1 (https=) |
| EP (1) | EP3675826B1 (https=) |
| JP (2) | JP7379325B2 (https=) |
| CN (1) | CN111065377A (https=) |
| AU (1) | AU2018324345B2 (https=) |
| CA (1) | CA3073851A1 (https=) |
| LT (1) | LT3675826T (https=) |
| WO (1) | WO2019045897A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11690921B2 (en) * | 2018-05-18 | 2023-07-04 | Sangamo Therapeutics, Inc. | Delivery of target specific nucleases |
| WO2020212522A1 (en) | 2019-04-16 | 2020-10-22 | Genfit | Compositions and methods for the stabilization of micro-rna |
| JP7699552B2 (ja) * | 2019-07-03 | 2025-06-27 | ファクター バイオサイエンス インコーポレイテッド | カチオン性脂質及びその使用 |
| US10501404B1 (en) | 2019-07-30 | 2019-12-10 | Factor Bioscience Inc. | Cationic lipids and transfection methods |
| EP3865122A1 (en) * | 2020-02-11 | 2021-08-18 | Pantherna Therapeutics GmbH | Lipid composition and use thereof for delivery of a therapeutically active agent to endothelium |
| WO2024006937A1 (en) | 2022-06-30 | 2024-01-04 | Life Technologies Corporation | Lipid compositions for in vivo delivery |
| EP4642434A2 (en) | 2022-12-29 | 2025-11-05 | Life Technologies Corporation | Lipid compositions on the basis of ionizable lipids, use for delivery to immune cells |
| WO2024250133A1 (zh) * | 2023-06-05 | 2024-12-12 | 安徽医科大学第一附属医院 | 肺靶向纳米胶束、制备方法及应用 |
| WO2025189064A1 (en) | 2024-03-08 | 2025-09-12 | Genzyme Corporation | Lipid nanoparticles |
| WO2026030375A2 (en) | 2024-07-30 | 2026-02-05 | Genzyme Corporation | Lipid nanoparticles and methods of manufacture and use thereof |
| CN118576568B (zh) * | 2024-08-06 | 2024-11-26 | 北京悦康科创医药科技股份有限公司 | 一种药物组合物及其制备方法和应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US6028077A (en) | 1997-04-15 | 2000-02-22 | Rinehart; Kenneth L. | Crambescidin compounds |
| DK1129064T3 (da) | 1998-11-12 | 2008-04-28 | Invitrogen Corp | Transfektionsreagenser |
| JP2004512345A (ja) | 2000-11-02 | 2004-04-22 | スミスクライン・ビーチャム・コーポレイション | 受容体アンタゴニスト−脂質コンジュゲートおよびそれを含有するデリバリービヒクル |
| AU2002360762A1 (en) | 2001-12-19 | 2003-07-09 | Alza Corporation | Liposomal tumor necrosis factor compositions |
| US7745651B2 (en) | 2004-06-07 | 2010-06-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
| US20130189364A1 (en) | 2004-07-09 | 2013-07-25 | Robert Sabin | Compositions and methods of potentiating adjuvant pharmaceuticals targeting latent viral infections |
| GB0418172D0 (en) | 2004-08-13 | 2004-09-15 | Ic Vec Ltd | Vector |
| US20110165223A1 (en) * | 2008-01-02 | 2011-07-07 | The Johns Hopkins University | Antitumor Immunization by Liposomal Delivery of Vaccine to the Spleen |
| US9029338B2 (en) * | 2009-08-14 | 2015-05-12 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus |
| WO2011076807A2 (en) | 2009-12-23 | 2011-06-30 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| US20120136073A1 (en) * | 2010-11-15 | 2012-05-31 | Life Technologies Corporation | Amine-Containing Transfection Reagents and methods for making and using same |
| PL3586861T3 (pl) * | 2011-06-08 | 2022-05-23 | Translate Bio, Inc. | Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna |
| GR1008018B (el) | 2012-09-06 | 2013-10-29 | Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, | Λιπιδικα συμπλοκα αποτελουμενα απο ανιονικα λυσο-λιπιδια και η εφαρμογη αυτων |
| CN103296033B (zh) | 2013-05-28 | 2016-05-11 | 京东方科技集团股份有限公司 | 一种阵列基板及其制作方法 |
| JP2016528890A (ja) * | 2013-07-09 | 2016-09-23 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ＣＲＩＳＰＲ／Ｃａｓ系を用いるゲノム編集の治療用の使用 |
| SG10201811729PA (en) | 2013-12-12 | 2019-02-27 | Life Technologies Corp | Membrane-penetrating peptides to enhance transfection and compositions and methods for using same |
| WO2016011203A1 (en) | 2014-07-15 | 2016-01-21 | Life Technologies Corporation | Compositions with lipid aggregates and methods for efficient delivery of molecules to cells |
| ES2949540T3 (es) | 2015-06-19 | 2023-09-29 | Massachusetts Inst Technology | 2,5-piperazinadionas sustituidas con alquenilo y su uso en composiciones para suministrar un agente a un sujeto o una célula |
| CN107849567B (zh) | 2015-06-26 | 2024-07-23 | 苏州瑞博生物技术股份有限公司 | 一种siRNA、含有该siRNA的药物组合物和缀合物及它们的应用 |
| JP2018532404A (ja) | 2015-10-14 | 2018-11-08 | ライフ テクノロジーズ コーポレーション | リボ核タンパク質トランスフェクション薬剤 |
| US11690921B2 (en) * | 2018-05-18 | 2023-07-04 | Sangamo Therapeutics, Inc. | Delivery of target specific nucleases |
| CN112996519B (zh) * | 2018-09-04 | 2025-02-28 | 德克萨斯大学系统董事会 | 用于核酸的器官特异性递送的组合物和方法 |
-
2018
- 2018-07-17 EP EP18749995.9A patent/EP3675826B1/en active Active
- 2018-07-17 CA CA3073851A patent/CA3073851A1/en active Pending
- 2018-07-17 JP JP2020512589A patent/JP7379325B2/ja active Active
- 2018-07-17 CN CN201880056879.8A patent/CN111065377A/zh active Pending
- 2018-07-17 US US16/038,107 patent/US20190060482A1/en not_active Abandoned
- 2018-07-17 LT LTEPPCT/US2018/042555T patent/LT3675826T/lt unknown
- 2018-07-17 WO PCT/US2018/042555 patent/WO2019045897A1/en not_active Ceased
- 2018-07-17 AU AU2018324345A patent/AU2018324345B2/en active Active
-
2021
- 2021-07-16 US US17/378,466 patent/US12521447B2/en active Active
-
2023
- 2023-07-14 JP JP2023115742A patent/JP2023138526A/ja active Pending
-
2025
- 2025-12-10 US US19/415,525 patent/US20260108623A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7641308B2 (ja) | Ｒｎａ送達のためのイオン化可能なカチオン性脂質 | |
| JP7606722B1 (ja) | カチオン性脂質化合物、それを含む組成物及びその用途 | |
| US6056938A (en) | Cationic lipids and the use thereof | |
| Montier et al. | Progress in cationic lipid-mediated gene transfection: a series of bio-inspired lipids as an example | |
| US20260108623A1 (en) | Cationic lipid compositions for tissue-specific delivery | |
| CN104428005A (zh) | 用于反义寡核苷酸递送的脂质纳米颗粒组合物 | |
| JP7708388B2 (ja) | 荷電物質を送達する脂質、その製剤、およびその製造方法 | |
| US20190328665A1 (en) | Liposome compositions encapsulating modified cyclodextrin complexes and uses thereof | |
| JPWO2023044343A5 (https=) | ||
| JPWO2019045897A5 (https=) | ||
| JP7829485B2 (ja) | がんの処置において有用なＴｏｌｌ様受容体（「ＴＬＲ」）アゴニストプロドラッグを含有する製剤化および／または共製剤化リポソーム組成物ならびにその方法 | |
| KR102465349B1 (ko) | 신규 이온화 지질 및 이를 포함하는 지질 나노입자 | |
| AU2001254548B2 (en) | Enhanced stabilised plasmid-lipid particle-mediated transfection using endosomal membrane | |
| JPWO2023044333A5 (https=) | ||
| KR20020063875A (ko) | 핵산 및 약물 전달용 중성-양이온성 지질 | |
| AU2022277025A1 (en) | Thermally stable lipid-nucleic acid molecule formulations utilising metal organic framework (mof) shells | |
| WO2023246218A1 (zh) | 用于核酸递送的可电离脂质及其组合物 | |
| JP2010518012A (ja) | カンプトテシン誘導体を含む医薬組成物 | |
| US12064512B2 (en) | Silyl lipids suitable for enhanced delivery of anti-viral therapeutics | |
| US7524981B2 (en) | Phospholipid derivatives and process for the production there | |
| JP2025525597A (ja) | アミノ脂質化合物、その製造方法およびその利用 | |
| JP2003522203A (ja) | 天然に存在しない核酸組成物、核酸を細胞中にトランスフェクションするのに有用な処方物の調製のためのそれらの使用、および応用 | |
| WO2006086992A2 (en) | Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands | |
| JP4904573B2 (ja) | 目的物質の脳毛細血管内皮細胞への取り込みを亢進させるための組成物 | |
| CN118221556A (zh) | 一种可电离阳离子脂质材料及其制备方法和应用 |